LIVE #WCLC26 — live KOL coverage of the World Conference on Lung Cancer View Full Coverage →
KOL Pulse

AI in Oncology — KOL Digest

KOL DigestFriday, September 18, 2026 All editions →

MSK opens its cancer knowledge to OpenEvidence — and OpenAI comes for the clinician desktop

MSK × OpenEvidenceChatGPT for CliniciansAI peer reviewWCLC26 AI taskforce
OpenEvidence — profile photo, @OpenEvidence on X
OpenEvidenceCompany@OpenEvidence on X
AI medical information platform
Today, Memorial Sloan Kettering Cancer Center (MSK) and OpenEvidence announced a partnership to advance precision oncology. This partnership includes integration of OpenEvidence within MSK’s Epic workflow, and bringing OncoKB™, MSK's precision oncology knowledge base, directly into OpenEvidence for its broader use by physicians outside of @MSKCancerCenter.

“AI has the potential to fundamentally change how we translate an increasingly complex and rapidly expanding body of knowledge into better decisions for patients,” – Anaeze Offodile, M.D., Chief Strategy Officer at MSK.

Full press release:
mskcc.org/news-releases/… ↗
View post on X ↗
Yan Leyfman, MD — profile photo, @YLeyfman on X
Yan Leyfman, MD@YLeyfman on X
Physician - AI-driven oncology & cell therapy; MedNews Week director
What happens when one of the world’s deepest repositories of cancer knowledge becomes accessible to physicians far beyond the walls of an academic cancer center?

That may be the more important story behind the partnership between Memorial Sloan Kettering and OpenEvidence.

For years, precision oncology has faced a paradox: we have more molecular data and more targeted therapies than ever, yet translating that information into the right treatment for the right patient remains extraordinarily complex.

The implications of integrating MSK’s 14 years of precision oncology data into an AI clinical platform extend well beyond faster literature searches.

1️⃣ Expertise could become more geographically distributed.

A patient does not necessarily need to live near a major academic cancer center for their physician to access specialized molecular oncology knowledge. If implemented effectively, this could narrow some of the gap between tertiary centers and community oncology.

2️⃣ Precision oncology could become more actionable.

We often talk about biomarker testing as if identifying a mutation is the endpoint.

It isn’t.

The real challenge is connecting a molecular alteration to the relevant evidence, available therapies, clinical trials, and ultimately a treatment decision. AI could increasingly serve as the layer connecting those pieces.

3️⃣ Clinical trial matching could become fundamentally different.

This may be one of the most consequential applications.

Rare cancers and uncommon molecular subsets are difficult to study partly because eligible patients are difficult to identify. A tool used across a large physician network could potentially help connect patients with specialized trials much earlier.

4️⃣ The same data infrastructure could eventually influence drug discovery.

The particularly interesting—and still highly experimental—next step is using aggregated clinical and molecular knowledge not only to retrieve evidence, but to generate hypotheses about new therapies, drug combinations, and repurposing opportunities.

That represents a shift from:

AI as a clinical search engine → AI as a clinical reasoning layer → AI as a translational research engine.

But there is an important caveat.

More data does not automatically produce better medicine.

The value will depend on data quality, representativeness, molecular testing rates, rigorous validation, transparency, and whether AI recommendations actually improve clinical outcomes rather than simply making information easier to retrieve.

The ultimate test will not be how many questions the system can answer.

It will be whether a patient in a community practice, who previously might never have received molecular testing or found a relevant clinical trial, has a meaningfully different set of options because this infrastructure exists.

That is where the promise of AI in oncology becomes much bigger than AI itself.

It becomes a question of whether we can turn concentrated expertise into something that is accessible, scalable, and ultimately actionable for every patient.

forbes.com/sites/innovati… ↗

#Oncology #PrecisionOncology #ArtificialIntelligence #AIinHealthcare #CancerResearch #ClinicalTrials #DrugDiscovery #DigitalHealth #Hematology #CancerCare @MSKCancerCenter @MSK_DeptOfMed @OpenEvidence
View post on X ↗
Michael Albert, MD — profile photo, @MichaelAlbertMD on X
Michael Albert, MD@MichaelAlbertMD on X
Physician
ChatGPT for Clinicians. Looks like you can sign a BAA and also earn CME. They are coming after OpenEvidence. chatgpt.com/plans/clinicia… ↗
View post on X ↗
Free Access · KOL Pulse Intelligence

Track oncology’s top KOLs in your specialty

Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:

  • Enhanced KOL profiles
  • Pharma influence & potential advisory-board patterns
  • 2025 Open Payments financial analysis
  • Social-media sentiment & trend signals
Get free access — pick your specialty
Choose the tumor types you follow. No cost, unsubscribe anytime.
Karan Singhal — profile photo, @thekaransinghal on X
Karan SinghalCompany executive@thekaransinghal on X
Health AI lead, OpenAI
Verified U.S. clinicians can get free GPT-6 Astra (Pro) access today via ChatGPT for Clinicians.

Sign up: chatgpt.com/plans/clinicia… ↗
View post on X ↗
Matt Spraker — profile photo, @SprakerMDPhD on X
Matt Spraker@SprakerMDPhD on X
Radiation oncologist
I use OE like a brilliant trainee that follows me around in clinic.

Safe answers to all my pimping questions, with citations.

If Darwin and Claude and Gemini want to do an ERAS style battle to impress me, I’m here for it.

Congrats on your score Darwin. Such a gunner. x.com/OpenEvidence/s… ↗
View post on X ↗
gilberto lopes — profile photo, @GlopesMd on X
gilberto lopes@GlopesMd on X
Medical oncologist - thoracic; University of Miami
Key findings:
• OpenEvidence highest expert concordance: τ=0.561
• Grok lowest expert divergence: JS=0.275
• Gemini + ASCO AI highest pairwise concordance: τ=0.876
• No single AI system was consistently superior
View post on X ↗
Eric Topol — profile photo, @EricTopol on X
Eric Topol@EricTopol on X
Physician-scientist (cardiology), Scripps - AI in medicine
Agentic AI for support of medical decision making.
Not real world but some encouraging progress for future deployment @NatureMedicine @jnkath
nature.com/articles/s4159… ↗
View post on X ↗
The clinician's role in the AI medical era
"Clinicians cannot, and should not, resist powerful AI technologies if these systems improve the quality of patient care."
"We contend that the clinician's enduring role is accountability."
[I think the enduring role is well beyond that, but OK]
perspective by @andrewparsonsMD and @AdamRodmanMD @AnnalsofIM
acpjournals.org/doi/10.7326/AN… ↗
View post on X ↗
Razelle Kurzrock, MD — profile photo, @Dr_R_Kurzrock on X
Razelle Kurzrock, MD@Dr_R_Kurzrock on X
Medical oncologist - precision oncology (Medical College of Wisconsin)
Special thanks to the AI agents who are now doing a lot of peer review and are responsible for reviews that all sound alike, are very long, and require fourth revisions which was previously unheard of. We are also appreciative of the occasional hallucinated reference suggestions
View post on X ↗
Yakup Ergün — profile photo, @dr_yakupergun on X
Yakup Ergün@dr_yakupergun on X
Medical oncologist - Bower Hospital
We seriously need to discuss the use of AI in scientific peer review.

Yesterday, we prepared a ~15-page response to a reviewer. We addressed every comment individually and revised the manuscript accordingly.

About 12 hours later, the same reviewer came back with another 2 pages of comments. And these were not simply an assessment of whether we had adequately addressed the original concerns. There were new analyses, new technical details, and new requests that had never been raised in the first round.

Is it humanly possible to carefully read a 15-page response letter, check the revised manuscript and all the changes, critically evaluate them, and then develop an entirely new set of methodological requests within 12 hours?

Perhaps. But it certainly raises questions.

With AI, you can generate an endless list of things authors “could also do”:

“Please perform this subgroup analysis.”
“Add another sensitivity analysis.”
“Repeat the analysis using a different model.”
“Adjust for this additional variable.”
“Validate the findings using another statistical method.”

There is literally no end to this.

And this is not just about whether reviewers use AI. The bigger problem is peer review turning into moving goalposts. Authors address the first-round concerns, only to find that the goalposts have moved and an entirely new set of requests appears in the next round.

Journals need clear rules for AI-assisted peer review. AI use should be disclosed, and unless a genuinely new and critical issue is identified, subsequent review rounds should primarily assess whether the original concerns were adequately addressed.

Otherwise, peer review risks becoming an endless AI prompt loop rather than scientific evaluation.

I fully recognize how difficult it has become for journals to find reviewers, and I am among those who criticize many aspects of the current academic publishing system. But please, if you volunteer to review a paper, don’t make an already exhausting process even more exhausting for authors. Enough is enough.
View post on X ↗
Hidehito HORINOUCHI — profile photo, @HHorinouchi on X
Hidehito HORINOUCHI@HHorinouchi on X
Thoracic medical oncologist - NCC Japan; IASLC AI Taskforce
🤖Experienced Big Wave of #AI in #WCLC26 ?
🔥Join Us! @IASLC #AI Artificial Intelligence Taskforce Survey
🆙 @IASLC #AI Taskforce
☑️Leads: @mihaela_aldea @SeastedtMD Dr. Muhammad Rafiqul Islam
🎯Parallel, mutually complementary surveys for physicians and patients
🎯Addressing global challenges in AI accessibility
▶️Patient: iaslc.co1.qualtrics.com/jfe/form/SV_eQ… ↗
▶️Physician: iaslc.co1.qualtrics.com/jfe/form/SV_cw… ↗
#LCSM @OncoAlert @Larvol
@ros1cancer @ROS1CancerSpain @LUNGevity @GO2forLungCancr @LungCancerEu @ALKPositiveinc @ALKpositiveINT @EGFRResisters @Exon20Group @kRasKickers @metcrusaders @BrafBombers @RETpositive @RETRenegades @NTRKers
*Image Created by @HHorinouchi with Gemini
View post on X ↗
Roberto Ferrara — profile photo, @RobertoFerrara_ on X
Roberto Ferrara@RobertoFerrara_ on X
Thoracic medical oncologist - Milan
A comprehensive and elegant talk on the state of the art of AI in lung cancer from @PrelajArsela..presented data from I3lung with concomitant Nat Med publication. @AI_ON_Lab
View post on X ↗
Yüksel Ürün — profile photo, @DrYukselUrun on X
Yüksel Ürün@DrYukselUrun on X
Medical oncologist - Ankara University
AI is no longer knocking. It is already inside…

If AI is solving 90-year-old math, the future is not coming slowly. Are we ready to update our lives, not just our phones? @DeryaTR_ x.com/openai/status/… ↗
View post on X ↗
Roupen Odabashian — profile photo, @RoupenMD on X
Roupen Odabashian@RoupenMD on X
Oncologist - Karmanos; health-tech builder
60% of Cleveland Clinic clinicians on an ambient scribe said it made them more likely to stay in practice.

Most physicians still haven't tried one.

55 minutes of live demos: Heidi, OpenEvidence, Doximity. Free, no sponsor:

youtube.com/playlist?list=… ↗
View post on X ↗
Most physicians have an app idea. Almost none will ever build it, because the gap between "my clinic needs this" and "I can ship this" was always measured in years.

That gap is now about a weekend.

44 minutes on vibe coding for physicians, free:

youtube.com/watch?v=t39BNG… ↗
View post on X ↗
Talha Badar — profile photo, @TalhaBadarMD on X
Talha Badar@TalhaBadarMD on X
Hematologist-oncologist - Mayo Clinic
#A_Day_at_work

Most people see the clinic visit. What they don’t see is everything happening behind the scenes.

👇🏽 This is how copilot summaries by inbox activity today: 😇

✅ Reviewing and supporting a translational research proposal aimed at personalizing treatment for patients with aggressive blood cancers.

✅ Responding to clinical operations issues to help ensure patients are scheduled with the right specialists and receive the most appropriate care.

✅ Reviewing and approving research protocol modifications to help advance ongoing scientific studies.

✅ Coordinating with research teams, pharmacists, and clinical trial staff regarding enrollment of patients into cutting-edge studies.

✅ Reviewing manuscript drafts and collaborative research projects with national and international colleagues.

✅ Evaluating collaborative opportunities focused on the future role of artificial intelligence in medicine

✅ Addressing compliance and documentation requirements essential for patient safety, quality care, and regulatory standards.

✅ Following up on occupational health and safety matters requiring physician review and communication.

Throughout the day, the work moved constantly between:

🔬 Research
🩺 Patient care
📚 Education
🤝 Collaboration
📊 Administration
⚖️ Compliance
View post on X ↗
Valerio Capraro — profile photo, @ValerioCapraro on X
Valerio CapraroAcademic scientist@ValerioCapraro on X
Associate Professor, University of Milan-Bicocca
Nature has just published a pretty incredible paper.

The authors introduce a framework that turns research papers into interactive AI agents.

Rather than engaging with a paper only as static text, researchers can question its agent, ask it to reproduce an analysis, or apply the paper’s methods to new data.

This could make research methods much easier to understand, reproduce, and use.

It also opens up a strange possibility: research papers that can, in a sense, talk to one another. The authors demonstrate this by connecting agents derived from different papers so that they can combine their methods and data.

Used carefully (and with human scientific judgment still firmly in the loop) this could become a powerful new form of scientific communication.

*

Full paper in the first reply
View post on X ↗
tatsunori_shimoi 下井辰徳 — profile photo, @shimoi_oncology on X
tatsunori_shimoi 下井辰徳@shimoi_oncology on X
Medical oncologist - NCC Japan (breast, sarcoma, rare cancers)
The Virtual Biotech: A multi-agent AI framework for therapeutic discovery and development | Science science.org/doi/10.1126/sc… ↗
View post on X ↗
The ASCO Post — profile photo, @ASCOPost on X
The ASCO PostPublication@ASCOPost on X
Oncology news publication (ASCO)
🖥️ #ASCOAI: At @ClevelandClinic A.I. Summit, Pete Clardy, MD, of @GoogleForHealth explored how AI could reshape clinical decision-making, training, & clinician-patient relationships.

@jamecancerdoc

🔗 ascoai.org/articles/2026/… ↗
Pete Clardy, MD of Google Health presenting at the Cleveland Clinic A.I. Summit lecture hall - audience in tiered seating, Cleveland Clinic podium
View post on X ↗
Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Quotes are verbatim from their authors’ public posts on X. Last updated September 18, 2026.